Loading stock data…
Aligos Therapeutics, Inc. (ALGS)
$6.21-0.01 (-0.16%)
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aligos Therapeutics, Inc. in the Healthcare sector is trading at $6.21 with a market capitalization of $39M. Wall Street consensus targets $53.43 (7 analysts), implying a +760.4% move over the next 12 months. The stock is currently 55% below its 52-week high of $13.69, remaining 13.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +760.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.83M↑ | $169,000↓ | $741,000↓ | $965,000↑ | $311,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$26.93M↓ | -$21.81M↑ | -$28.36M↓ | -$18.57M↑ | -$19.24M |
| Net Income | -$23.04M↓ | -$19.88M↑ | -$31.54M↓ | -$15.86M↓ | $43.09M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$38.78M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-238.24%
Volume
Today's trading volume
20,288
Recent News
Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates
Aligos Therapeutics (NASDAQ:ALGS) shares rose 7. 6% to $6.
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal
The payment gives Aligos non-dilutive funding as it advances its pipeline of treatments for liver and viral diseases.
Aligos and Xiamen Amoytop sign deal for HBV therapy
Aligos remains eligible for up to $420m in milestones and tiered, high single-digit royalties on Amoytop’s net sales.
Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.